Compare FHB & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHB | PBLS |
|---|---|---|
| Founded | 1858 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2016 | 2026 |
| Metric | FHB | PBLS |
|---|---|---|
| Price | $26.14 | $26.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $29.11 | ★ $41.75 |
| AVG Volume (30 Days) | ★ 1.8M | 964.3K |
| Earning Date | 10-23-2026 | 11-17-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ 22.91 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $880,788,000.00 | N/A |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $53.05 | $222.58 |
| P/E Ratio | $22.07 | ★ N/A |
| Revenue Growth | ★ 8.94 | N/A |
| 52 Week Low | $23.26 | $22.78 |
| 52 Week High | $30.58 | $42.49 |
| Indicator | FHB | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 42.16 |
| Support Level | $25.20 | $26.42 |
| Resistance Level | $26.18 | $41.72 |
| Average True Range (ATR) | 0.44 | 2.39 |
| MACD | 0.18 | 0.18 |
| Stochastic Oscillator | 99.26 | 54.64 |
First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.